Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies

NCT00215605 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT00215605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00215605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies
Lead sponsor
Exelixis
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2005
Completion date
July 31, 2012
Enrollment
85 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, lymphoma, thyroid carcinoma